ReviewMini reviews in medicinal chemistry2026
Retrospection of
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Argemone mexicana (Linn.), commonly known as prickly poppy, is a well-documented medicinal plant in Indian Ayurvedic literature, recognized for its diverse pharmacological properties. It has been investigated for its potential applications in the treatment of cancer, inflammation, and wound healing, thereby highlighting its pharmacological significance. Traditionally, it has been used successfully to treat skin diseases, ulcers, tumors, boils, and snake venom poisoning. The therapeutic potential of this plant has been further validated by recent studies, which also demonstrated its safety in clinical trials for antimalarial activity. Berberine, argemonine, argenaxine, and chelerythrine are among the bioactive alkaloids abundant in Argemone mexicana, shown to possess significant anticancer, antibacterial, anti-inflammatory, and antimalarial properties. These compounds exert cytotoxic effects against various cancer cell lines by modulating key oncogenic pathways and preventing the acquisition of cancer hallmark characteristics, such as uncontrolled proliferation, apoptosis evasion, inflammation, invasion, angiogenesis, and drug resistance. Preclinical studies have further explored the role of Argemone mexicana in cancer treatment and wound healing, expanding its pharmacological relevance. This review systematically compiles evidence from in vitro and in vivo studies, elucidating the mechanisms through which Argemone mexicana and its derived compounds exhibit anticancer activity. By highlighting its potential as a natural source of anticancer agents, this review aims to provide a foundation for future research and the development of novel plant-based cancer therapeutics.
Indexed as
Identifiers
41863239What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.